Iloprost Rafarm

Iloprost, the active ingredient in Iloprost Rafarm, is a prostacyclin analog presented as an inhalation solution for inhalation use. It is indicated for the treatment of pulmonary arterial hypertension and for managing digital ulcers associated with systemic sclerosis in adult patients. The drug works by dilating pulmonary vessels and inhibiting platelet aggregation, thereby improving blood flow and oxygen delivery.

GNH USA supplies Iloprost Rafarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with reliable logistics and regulatory support.

Iloprost is used in the pulmonary vascular and connective‑tissue disease pathways to improve vascular function.

Pulmonary arterial hypertension: reduces pulmonary arterial pressure and improves exercise capacity. Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces new ulcer formation. Systemic sclerosis‑related digital vasculopathy: decreases the frequency of new digital ulcers.

Common Side Effects: - Cough or throat irritation - Headache - Flushing or warmth sensation - Nausea or dyspepsia - Dizziness or light‑headedness - Nasal congestion

Serious or Rare Side Effects: - Severe hypotension - Pulmonary edema - Significant bleeding events - Acute bronchospasm - Cardiac arrhythmias - Anaphylactoid reactions

Before initiating therapy, consider the following precautions: - Monitor blood pressure: check for hypotension before and during therapy. - Assess respiratory status: watch for cough, bronchospasm, or throat irritation. - Avoid in severe heart failure: risk of worsening cardiac function. - Pregnancy considerations: use only if potential benefit justifies risk to fetus. - Drug interaction review: evaluate concomitant vasodilators and anticoagulants. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Iloprost may interact with several agents; review concomitant medications carefully.

Major Interactions (Avoid): - Epoprostenol: additive vasodilation may cause severe hypotension. - Sildenafil: combined pulmonary vasodilators increase risk of profound hypotension. - Warfarin: enhanced antiplatelet effect may lead to bleeding.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may augment hypotensive effect, require monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect platelet function and increase bleeding risk.